ClinicalTrials.gg
CompletedNCT02030067Updated Dec 6, 2023Results posted

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

A Phase 1/2 interventional study of RX-3117 in Solid Tumor and Metastatic Bladder Cancer, sponsored by Processa Pharmaceuticals. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Processa Pharmaceuticals · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
127
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Enrollment
185th of 715
127 · median 46
Started
2013
with 26 others
Phase 1/2
83 of 883
14 open now
Registered
297th of 883
by date

Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 185th largest by enrollment of the 715 interventional ones that give a count, is one of 27 that started in 2013, is one of 83 in phase 1/2, and was the 297th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 883 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).

Read the detailed description

This is a dose-finding, open-label, single agent study of RX-3117. Once the maximum tolerated dose is identified additional subjects will be treated in a dose expansion followed by a 2-stage Phase 2 study. Subjects will be treated for up to 8 cycles of therapy. A cycle will be 4 weeks. RX-3117 dosing will be 3 times each week for 3 weeks follow by 1 week off treatment. All subjects will be followed for at least 30 days after the last dose of RX-3117.

03

Conditions studied

  • Solid Tumor
  • Metastatic Bladder Cancer

Keywords

  • oncology
  • tumor
  • metastatic
  • bladder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females who are 18 years or older
  • Able to swallow capsules
  • Histological or cytological evidence of confirmed pancreatic or advanced bladder cancer
  • Able to discontinue all anticancer therapies 2 weeks prior to study start
  • Measurable or evaluable disease using
  • of at least 3 months
  • performance status of 0 or 1
  • Provide written

Exclusion criteria

Exclusion Criteria:

  • Primary brain tumors or clinical evidence of active
  • Systemic use within 7 days before planned start of study therapy
  • Active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy
  • Uncontrolled diabetes as assessed by the investigator
  • Prior or current history of , or
  • History of bone marrow of solid organ transplantation
  • History of congestive heart failure, arrhythmias, acute coronary syndrome or torsades de pointes
  • Any other medical, psychiatric, or social condition, which in the opinion of the investigator, would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results
  • Known to gemcitabine, azacytidine or cytosine arabinoside
  • Pregnant, planning a pregnancy or breast feeding during the study
  • Concurrent participation in another therapeutic clinical trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    RX-3117

    All subjects will receive RX-3117.

    Drug: RX-3117

Interventions

  • DrugRX-3117
06

What researchers measure

Primary outcomes

  1. Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1

    Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days)

    Time frame: 28 days

  2. Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1

    Number of subjects participating in Phase 1 that experience any SAEs

    Time frame: through study completion, up to 224 days (8 cycles of treatment)

  3. Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1

    Number of subjects participating in Phase 1 of study that discontinued study treatment due to a treatment emergent adverse event.

    Time frame: through study completion, up to 224 days (8 cycles of treatment)

  4. Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1

    Number of subjects that experience any treatment-related adverse event.

    Time frame: through study completion, up to 224 days (8 cycles of treatment)

  5. Progression Free Survival (Phase 2)

    Progression Free Survival in Phase 2 of the study for pancreatic and bladder cancer subjects.

    Time frame: 4 months

Secondary outcomes

  1. Area Under the Plasma Concentration Time Curve (AUC) (Phase 1)

    Time frame: Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15

  2. Best Overall Response Rate (Phase 2)

    Best Overall Response Rate (includes Complete Response, Partial Response, and Stable Disease)

    Time frame: Baseline and at 4, 8, 12, 16 and 32 weeks

Other outcomes

  1. Biomarker Concentrations in Blood (Phase 1 and Phase 2)

    Analysis of biomarker data not conducted. Biomarker samples were not analyzed due to previous sponsor terminating clinical program.

    Time frame: Baseline and 4, 8, 12, 16 and 32 weeks

07

Results

Posted Dec 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneRX-3117 30 mg, 3 Times/WeekRX-3117 60 mg, 3 Times/WeekRX-3117 100 mg, 3 Times/WeekRX-3117 150 mg, 3 Times/WeekRX-3117 200 mg, 3 Times/WeekRX-3117 500 mg, 3 Times/WeekRX-3117 1000 mg, 3 Times/WeekRX 3117 1500 mg, 3 Times/WeekRX-3117 2000 mg, 3 Times/WeekRX-3117 500 mg, 5 Times/WeekRX-3117 700 mg, 5 Times/WeekRX-3117 500 mg, 7 Times/WeekRX-3117 700 mg 5 Times/Week (Phase 2 Portion of Study)
Started113333346311380
Completed0010000000000
Not completed112333346311380
Withdrew: Disease progression11223233437259
Withdrew: Withdrawal by subject0001000100306
Withdrew: Physician decision0000000000103
Withdrew: Other reasons0000010020004
Withdrew: Adverse event0000000000018

Outcome measures

PrimaryOverall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1

Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days)

Time frame:
28 days
Reported as:
Count of participants · Participants
Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1
ParticipantsRX-3117 30 mg, 3 Times/WeekRX-3117 60 mg, 3 Times/WeekRX-3117 100 mg, 3 Times/WeekRX-3117 150 mg, 3 Times/WeekRX-3117 200 mg, 3 Times/WeekRX-3117 500 mg, 3 Times/WeekRX-3117 1000 mg, 3 Times/WeekRX 3117 1500 mg, 3 Times/WeekRX-3117 2000 mg, 3 Times/WeekRX-3117 500 mg, 5 Times/WeekRX-3117 700 mg, 5 Times/WeekRX-3117 500 mg, 7 Times/Week
Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1000000001002
PrimaryOverall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1

Number of subjects participating in Phase 1 that experience any SAEs

Time frame:
through study completion, up to 224 days (8 cycles of treatment)
Reported as:
Count of participants · Participants
Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1
ParticipantsRX-3117 30 mg, 3 Times/WeekRX-3117 60 mg, 3 Times/WeekRX-3117 100 mg, 3 Times/WeekRX-3117 150 mg, 3 Times/WeekRX-3117 200 mg, 3 Times/WeekRX-3117 500 mg, 3 Times/WeekRX-3117 1000 mg, 3 Times/WeekRX 3117 1500 mg, 3 Times/WeekRX-3117 2000 mg, 3 Times/WeekRX-3117 500 mg, 5 Times/WeekRX-3117 700 mg, 5 Times/WeekRX-3117 500 mg, 7 Times/Week
Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1010000102251
PrimaryOverall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1

Number of subjects participating in Phase 1 of study that discontinued study treatment due to a treatment emergent adverse event.

Time frame:
through study completion, up to 224 days (8 cycles of treatment)
Reported as:
Count of participants · Participants
Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1
ParticipantsRX-3117 30 mg, 3 Times/WeekRX-3117 60 mg, 3 Times/WeekRX-3117 100 mg, 3 Times/WeekRX-3117 150 mg, 3 Times/WeekRX-3117 200 mg, 3 Times/WeekRX-3117 500 mg, 3 Times/WeekRX-3117 1000 mg, 3 Times/WeekRX 3117 1500 mg, 3 Times/WeekRX-3117 2000 mg, 3 Times/WeekRX-3117 500 mg, 5 Times/WeekRX-3117 700 mg, 5 Times/WeekRX-3117 500 mg, 7 Times/Week
Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1000000000101
PrimaryOverall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1

Number of subjects that experience any treatment-related adverse event.

Time frame:
through study completion, up to 224 days (8 cycles of treatment)
Reported as:
Count of participants · Participants
Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1
ParticipantsRX-3117 30 mg, 3 Times/WeekRX-3117 60 mg, 3 Times/WeekRX-3117 100 mg, 3 Times/WeekRX-3117 150 mg, 3 Times/WeekRX-3117 200 mg, 3 Times/WeekRX-3117 500 mg, 3 Times/WeekRX-3117 1000 mg, 3 Times/WeekRX 3117 1500 mg, 3 Times/WeekRX-3117 2000 mg, 3 Times/WeekRX-3117 500 mg, 5 Times/WeekRX-3117 700 mg, 5 Times/WeekRX-3117 500 mg, 7 Times/Week
Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1012330236393
PrimaryProgression Free Survival (Phase 2)

Progression Free Survival in Phase 2 of the study for pancreatic and bladder cancer subjects.

Time frame:
4 months
Reported as:
Median · weeks
Progression Free Survival (Phase 2)
weeksRX-3117 700 mg 5 Times/Week (Phase 2 Portion of Study)
Pancreatic cancer patients4.7 (3.14 to 8.00)
Bladder cancer patients7.7 (7.14 to 13.00)
SecondaryArea Under the Plasma Concentration Time Curve (AUC) (Phase 1)
Time frame:
Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15

No measurements were reported for this outcome.

SecondaryBest Overall Response Rate (Phase 2)

Best Overall Response Rate (includes Complete Response, Partial Response, and Stable Disease)

Time frame:
Baseline and at 4, 8, 12, 16 and 32 weeks
Reported as:
Number · percentage
Best Overall Response Rate (Phase 2)
percentageRX-3117 700 mg 5 Times/Week (Phase 2 Portion of Study)
pancreatic subjects26.8 (14.2 to 42.9)
bladder subjects45.2 (27.3 to 64.0)
Other pre-specifiedBiomarker Concentrations in Blood (Phase 1 and Phase 2)

Analysis of biomarker data not conducted. Biomarker samples were not analyzed due to previous sponsor terminating clinical program.

Time frame:
Baseline and 4, 8, 12, 16 and 32 weeks

No measurements were reported for this outcome.

Adverse events

Collected over up to 224 days (8 cycles of treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 (Dose Escalation) 30 mg 3x/Week0/1 (0%)0/1 (0%)1/1 (100%)
Phase 1 (Dose Escalation) 60 mg 3x/Week0/1 (0%)1/1 (100%)1/1 (100%)
Phase 1 (Dose Escalation) 100 mg 3x/Week0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 (Dose Escalation) 150 mg 3x/Week0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 (Dose Escalation) 200 mg 3x/Week0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 (Dose Escalation) 500 mg 3x/Week0/3 (0%)0/3 (0%)0/3 (0%)
Phase 1 (Dose Escalation) 1000 mg 3x/Week0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 1 (Dose Escalation) 1500 mg 3x/Week0/4 (0%)0/4 (0%)4/4 (100%)
Phase 1 (Dose Escalation) 2000 mg 3x/Week0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase 1 (Dose Escalation) 500 mg 5x/Week0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase 1 (Dose Escalation) 700 mg 5x/Week1/11 (9.1%)5/11 (45.5%)11/11 (100%)
Phase 1 (Dose Escalation) 500 mg 7x/Week0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 2 700 mg8/80 (10%)29/80 (36.3%)78/80 (97.5%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPhase 1 (Dose Escalation) 30 mg 3x/WeekPhase 1 (Dose Escalation) 60 mg 3x/WeekPhase 1 (Dose Escalation) 100 mg 3x/WeekPhase 1 (Dose Escalation) 150 mg 3x/WeekPhase 1 (Dose Escalation) 200 mg 3x/WeekPhase 1 (Dose Escalation) 500 mg 3x/WeekPhase 1 (Dose Escalation) 1000 mg 3x/WeekPhase 1 (Dose Escalation) 1500 mg 3x/WeekPhase 1 (Dose Escalation) 2000 mg 3x/WeekPhase 1 (Dose Escalation) 500 mg 5x/WeekPhase 1 (Dose Escalation) 700 mg 5x/WeekPhase 1 (Dose Escalation) 500 mg 7x/WeekPhase 2 700 mg
hypoglycemiaMetabolism and nutrition disorders0/11/10/30/30/30/30/30/40/60/30/110/30/80
pneumoniaInfections and infestations0/10/10/30/30/30/31/30/40/61/30/110/30/80
stomatitisGastrointestinal disorders0/10/10/30/30/30/30/30/40/60/30/111/30/80
vomitingGastrointestinal disorders0/10/10/30/30/30/30/30/40/61/30/110/30/80
cerebrovascular accidentNervous system disorders0/10/10/30/30/30/30/30/40/61/30/110/31/80
pleurisyRespiratory, thoracic and mediastinal disorders0/10/10/30/30/30/30/30/40/61/30/110/30/80
anemiaBlood and lymphatic system disorders0/10/10/30/30/30/30/30/41/60/30/110/30/80
neutropeniaBlood and lymphatic system disorders0/10/10/30/30/30/30/30/41/60/30/110/30/80
urinary tract obstructionRenal and urinary disorders0/10/10/30/30/30/30/30/41/60/30/110/31/80
haematemesisGastrointestinal disorders0/10/10/30/30/30/30/30/40/60/31/110/30/80
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPhase 1 (Dose Escalation) 30 mg 3x/WeekPhase 1 (Dose Escalation) 60 mg 3x/WeekPhase 1 (Dose Escalation) 100 mg 3x/WeekPhase 1 (Dose Escalation) 150 mg 3x/WeekPhase 1 (Dose Escalation) 200 mg 3x/WeekPhase 1 (Dose Escalation) 500 mg 3x/WeekPhase 1 (Dose Escalation) 1000 mg 3x/WeekPhase 1 (Dose Escalation) 1500 mg 3x/WeekPhase 1 (Dose Escalation) 2000 mg 3x/WeekPhase 1 (Dose Escalation) 500 mg 5x/WeekPhase 1 (Dose Escalation) 700 mg 5x/WeekPhase 1 (Dose Escalation) 500 mg 7x/WeekPhase 2 700 mg
nauseaGastrointestinal disorders0/10/12/31/31/30/31/31/42/60/36/113/322/80
abdominal painGastrointestinal disorders1/10/10/30/30/30/30/30/40/60/33/110/323/80
fatigueGeneral disorders0/11/12/32/32/30/31/33/44/61/36/111/339/80
decreased appetiteMetabolism and nutrition disorders0/11/10/31/30/30/31/30/41/61/33/110/315/80
hypomagnesaemiaMetabolism and nutrition disorders1/10/10/31/30/30/31/30/40/60/30/110/34/80
coughRespiratory, thoracic and mediastinal disorders0/11/10/30/30/30/31/30/40/60/32/110/37/80
vomitingGastrointestinal disorders0/10/12/31/30/30/31/30/41/61/34/112/314/80
anaemiaBlood and lymphatic system disorders0/10/10/30/30/30/32/30/43/62/34/112/338/80
lymphocyte count decreasedInvestigations0/10/10/30/30/30/30/30/42/62/30/110/30/80
diarrhoeaGastrointestinal disorders0/10/10/30/30/30/30/30/40/60/30/110/337/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)RX-3117 30 mg 3 Times/WeekRX-3117 60 mg 3 Times/WeekRX-3117 100 mg 3 Times/WeekRX-3117 150 mg 3 Times/WeekRX-3117 200 mg 3 Times/WeekRX-3117 500 mg 3 Times/WeekRX-3117 1000 mg 3 Times/WeekRX-3117 1500 mg 3 Times/WeekRX-3117 2000 mg 3 Times/WeekRX-3117 500 mg 5 Times/WeekRX-3117 700 mg 5 Times/WeekRX-3117 500 mg 7 Times/WeekRX-3117 700 mg 5 Times/Week (Phase 2)Total
Mean69.0 ± 066.0 ± 065.3 ± 5.8667.0 ± 4.5868.0 ± 6.2453.7 ± 7.5754.3 ± 4.1663.3 ± 16.5061.0 ± 13.3062.0 ± 13.0858.0 ± 10.8767.0 ± 6.5667.6 ± 9.1165.37 ± 9.84
Sex: Female, Male
Sex: Female, Male(Participants)RX-3117 30 mg 3 Times/WeekRX-3117 60 mg 3 Times/WeekRX-3117 100 mg 3 Times/WeekRX-3117 150 mg 3 Times/WeekRX-3117 200 mg 3 Times/WeekRX-3117 500 mg 3 Times/WeekRX-3117 1000 mg 3 Times/WeekRX-3117 1500 mg 3 Times/WeekRX-3117 2000 mg 3 Times/WeekRX-3117 500 mg 5 Times/WeekRX-3117 700 mg 5 Times/WeekRX-3117 500 mg 7 Times/WeekRX-3117 700 mg 5 Times/Week (Phase 2)Total
Female0022223142833463
Male1111110321304661
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RX-3117 30 mg 3 Times/WeekRX-3117 60 mg 3 Times/WeekRX-3117 100 mg 3 Times/WeekRX-3117 150 mg 3 Times/WeekRX-3117 200 mg 3 Times/WeekRX-3117 500 mg 3 Times/WeekRX-3117 1000 mg 3 Times/WeekRX-3117 1500 mg 3 Times/WeekRX-3117 2000 mg 3 Times/WeekRX-3117 500 mg 5 Times/WeekRX-3117 700 mg 5 Times/WeekRX-3117 500 mg 7 Times/WeekRX-3117 700 mg 5 Times/Week (Phase 2)Total
Hispanic or Latino0111112031511431
Not Hispanic or Latino1022221432626390
Unknown or Not Reported00000000000033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RX-3117 30 mg 3 Times/WeekRX-3117 60 mg 3 Times/WeekRX-3117 100 mg 3 Times/WeekRX-3117 150 mg 3 Times/WeekRX-3117 200 mg 3 Times/WeekRX-3117 500 mg 3 Times/WeekRX-3117 1000 mg 3 Times/WeekRX-3117 1500 mg 3 Times/WeekRX-3117 2000 mg 3 Times/WeekRX-3117 500 mg 5 Times/WeekRX-3117 700 mg 5 Times/WeekRX-3117 500 mg 7 Times/WeekRX-3117 700 mg 5 Times/Week (Phase 2)Total
American Indian or Alaska Native00000000000000
Asian00000100000034
Native Hawaiian or Other Pacific Islander00000000000000
Black or African American000000110000810
White1133311353926499
More than one race00000000000000
Unknown or Not Reported000001101021511
08

Study locations

12 sites
  • Rexahn Site
    Birmingham, Alabama 35294, United States
  • Rexahn Site
    Tucson, Arizona 85724, United States
  • Rexahn Site
    Duarte, California 91010, United States
  • Rexahn Site
    Miami Lakes, Florida 33014, United States
  • Rexahn Site
    Miami, Florida 33136, United States
  • Rexahn Site
    Skokie, Illinois 60077, United States
  • Rexahn Site
    Saint Louis, Missouri 63110, United States
  • Rexahn Site
    Las Vegas, Nevada 89119, United States
  • Rexahn Site
    New York, New York 10021, United States
  • Rexahn Site
    San Antonio, Texas 78229, United States
  • Rexahn Site
    Salt Lake City, Utah 84112, United States
  • Rexahn Site
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jul 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2013
First posted
Jan 8, 2014
Start
Dec 2013
Primary completionActual
Jul 2019
CompletionActual
Dec 2019
Results first posted
Dec 6, 2023
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02030067
Lead sponsor
Processa Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 8, 2014
Start date
Dec 2013
Primary completion
Jul 2019
Completion
Dec 2019
Results posted
Dec 6, 2023
Last update
Dec 6, 2023

Study contacts

Ely Benaim, MD
study director · Rexahn Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion